Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.47 |
| ▸ | CTSL | P07711 | 6/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404949 | 0.91 | CTSK (0.50) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5093142 | 0.91 | CTSK (0.47) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5098745 | 0.91 | CTSK (0.47) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4766756 | 0.90 | CTSK (0.53) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5092914 | 0.89 | CTSK (0.52) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5099276 | 0.84 | CTSK (0.46) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5096605 | 0.84 | CTSK (0.50) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5096440 | 0.84 | CACNA1B (0.51) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4073953 | 0.83 | KMT2A (0.53) | MMP2MEN1KMT2AGAA | |
| SCHEMBL5106033 | 0.83 | CTSK (0.49) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | CTSK 47/4885CTSL 20/4885CTSS 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.